Is the presence of lymphovascular invasion associated with recurrence and progression in bladder cancer patients that have received adequate BCG therapy?
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Lymphovascular invasion (LVI) significantly predicts recurrence and progression in high-risk non-muscle-invasive bladder cancer (NMIBC) patients treated with Bacillus Calmette-Guérin (BCG). LVI presence indicates a higher risk of cancer returning or advancing, even with standard therapy.
Area Of Science
- Urology
- Oncology
- Pathology
Background
- Non-muscle-invasive bladder cancer (NMIBC) poses a risk of recurrence and progression.
- Bacillus Calmette-Guérin (BCG) is a standard treatment for high-risk NMIBC.
- Predictive factors for treatment outcomes in NMIBC are crucial for patient management.
Purpose Of The Study
- To evaluate lymphovascular invasion (LVI) as a predictor of recurrence and progression.
- To assess the impact of LVI on outcomes in high and very high-risk NMIBC patients undergoing BCG therapy.
Main Methods
- Retrospective analysis of 93 patients with high/very high-risk NMIBC treated with BCG.
- Comparison of recurrence and progression rates between patients with and without LVI.
- Univariate and multivariate regression analysis to identify independent predictors.
Main Results
- LVI was detected in 35.5% of patients.
- Patients with LVI had significantly higher rates of recurrence (51.5%) and progression (33.3%) compared to those without LVI (p < 0.001 and p = 0.04).
- LVI was identified as an independent predictor of recurrence (p = 0.001).
Conclusions
- Lymphovascular invasion is a significant independent predictor of recurrence in high-risk NMIBC patients treated with BCG.
- The presence of LVI warrants increased vigilance for recurrence and progression, with approximately one-third of affected patients experiencing recurrence within a year.
- LVI should be considered in risk stratification and treatment planning for NMIBC patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
